Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). [electronic resource]
Producer: 20070607Description: 2068-76 p. digitalISSN:- 0008-543X
- Aged
- Antineoplastic Agents -- therapeutic use
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Benzamides
- Disease-Free Survival
- Female
- Genes, abl
- Humans
- Imatinib Mesylate
- Male
- Middle Aged
- Piperazines -- adverse effects
- Precursor Cell Lymphoblastic Leukemia-Lymphoma -- drug therapy
- Protein Kinase Inhibitors -- therapeutic use
- Pyrimidines -- adverse effects
- Remission Induction
- Survival Rate
No physical items for this record
Publication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.